The global prurigo nodularis treatment market size accounted for USD 2.13 billion in 2023 and is predicted to grow around USD 3.17 billion by 2033, growing at a CAGR of 4.03% from 2024 to 2033.
Key Points
- The North America prurigo nodularis treatment market size accounted for USD 870 million in 2023 and is expected to attain around USD 1,300 million by 2033.
- North America dominated the market with the major market share of 41% in 2023.
- Asia Pacific is estimated to be the fastest growing during the forecast period of 2024-2033.
- By product type, the corticosteroids segment has held the biggest market share of 37% in 2023.
- By product type, the antihistamines segment is estimated to be the fastest growing during the forecast period.
- By distribution channel type, the retail pharmacies segment has contributed more than 42% of market share in 2023.
- By distribution channel type, the online pharmacies segment is expected to be the fastest growing during the forecast period.
The Prurigo Nodularis Treatment Market refers to the pharmaceutical and therapeutic landscape focused on addressing prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules or bumps on the skin. This market encompasses various treatment modalities aimed at managing symptoms, reducing itchiness, and improving the quality of life for patients suffering from this challenging dermatological condition.
Get a Sample: https://www.precedenceresearch.com/sample/4279
Growth Factors
The growth of the Prurigo Nodularis Treatment Market is driven by several factors. Firstly, an increasing awareness of prurigo nodularis among healthcare providers and patients has led to a higher diagnosis rate, thereby expanding the patient pool. Additionally, ongoing research and development efforts aimed at discovering more effective and targeted therapies have contributed to the growth of treatment options available for this condition. Moreover, the rising prevalence of skin disorders globally has underscored the need for innovative treatments for prurigo nodularis.
Region Insights
Regionally, the Prurigo Nodularis Treatment Market exhibits variations in terms of prevalence, treatment practices, and healthcare infrastructure. Developed regions such as North America and Europe often have a higher prevalence of prurigo nodularis cases and access to advanced treatment options. In contrast, emerging economies in Asia Pacific and Latin America are witnessing a growing awareness of the condition, leading to increased demand for effective treatments.
Prurigo Nodularis Treatment Market Scope
| Report Coverage | Details |
| Prurigo Nodularis Treatment Market Size in 2023 | USD 2.13 Billion |
| Prurigo Nodularis Treatment Market Size in 2024 | USD 2.22 Billion |
| Prurigo Nodularis Treatment Market Size by 2033 | USD 3.17 Billion |
| Growth Rate from 2024 to 2033 | CAGR of 4.03% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product Type and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Prurigo Nodularis Treatment Market Dynamics
Drivers
Key drivers propelling the growth of the Prurigo Nodularis Treatment Market include advancements in dermatological research, expanding healthcare expenditure, and increasing collaborations between pharmaceutical companies and research institutions. Additionally, a shift towards personalized medicine and the development of biologic therapies tailored to specific patient profiles are driving the market forward.
Opportunities:
There are significant opportunities within the Prurigo Nodularis Treatment Market, including the development of novel therapies targeting specific pathways implicated in the pathogenesis of prurigo nodularis. Moreover, expanding market penetration into emerging regions presents growth prospects for pharmaceutical companies and healthcare providers looking to address unmet medical needs in these areas.
Challenges:
Despite the promising growth prospects, the Prurigo Nodularis Treatment Market faces challenges such as regulatory hurdles associated with drug approvals, limited understanding of the underlying mechanisms of prurigo nodularis, and the high cost of biologic therapies. Additionally, ensuring equitable access to effective treatments across different socioeconomic strata remains a challenge in some regions. Addressing these challenges will be crucial for sustaining market growth and improving patient outcomes in the long term.
Read Also: Medical Gas Market Size to Worth USD 32.47 Billion by 2033
Prurigo Nodularis Treatment Market Recent Developments
- In February 2023, Pfizer’s supplemental new drug applications (NDA) for abrocitinib (CIBINQO) was announced by the United States (U.S.) Food and Drug Application (FDA) for the treatment of serious atopic dermatitis, refractory, skin clearance, itching, severity, and disease extent for the 12 to less than 18 years of age group.
- In October 2023, new positive pruritus data for VTAMA Cream from their essential phase 3 trials was announced by a clinical-stage biopharmaceutical company, Dermavant Sciences (tapinarof). This is for children as young as two years old, and 1% of adults suffer from atopic dermatitis. It is also important to reduce itching, burning, redness, and itching.
- In February 2024, the Food and Drug Administration (FDA) accepted Galderma’s BLA (biological license application) for Nemolizumab to treat atopic dermatitis and prurigo nodularis.
Prurigo Nodularis Treatment Market Companies
- Bayer AG
- Celgene Corporation
- Glaxo Smith Kline plc
- Galderma Takeda Pharmaceuticals (Nestle Skin Health Company)
- Johnson & Johnson Services Inc.
- Merk & Co. Inc
- Novartis AG
- Pfizer Inc
- Sanofi SA
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Inc
- VYNE Therapeutics Inc.
Segments Covered in the Report
By Product Type
- Antihistamines
- Capsaicin Cream
- Corticosteroids
- Emollients
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
